Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 102 (Search time: 0.001 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2015KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyYeung, D.; Tang, C.; Vidovic, L.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2014How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemiaRoss, D.; Hughes, T.
2017CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patientsBarratt, D.; Cox, H.; Menelaou, A.; Yeung, D.; White, D.; Hughes, T.; Somogyi, A.
2016ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatmentEadie, L.; Hughes, T.; White, D.; New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
2017CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsHughes, A.; Clarson, J.; Tang, C.; Vidovic, L.; White, D.; Hughes, T.; Yong, A.
2016BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaLatham, S.; Bartley, P.; Budgen, B.; Ross, D.; Hughes, E.; Branford, S.; White, D.; Hughes, T.; Morley, A.
2012Suboptimal responses in chronic myeloid leukemia: implications and management strategiesJabbour, E.; Saglio, G.; Hughes, T.; Kantarjian, H.
2012Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cellsWang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.
2010Practical considerations for monitoring patients with chronic myeloid leukemiaBranford, S.; Hughes, T.
2013Which TKI? An embarrassment of riches for chronic myeloid leukemia patientsHughes, T.; White, D.